J&J says Phase 3 FUZION trial shows TREMFYA delivers up to 28% perianal fistula remission in Crohn’s disease
JNJ•Johnson & Johnson said TREMFYA delivered up to 28% perianal fistula remission in its Phase 3 FUZION trial in Crohn’s disease.
1. FUZION trial results
Johnson & Johnson disclosed Phase 3 subgroup data for TREMFYA in Crohn’s disease patients with perianal fistulas, with remission rates of up to 28%. The company said results were being presented at the American College of Gastroenterology 2026 Annual Scientific Meeting and that safety findings matched the drug’s established profile in Crohn’s disease.
